R2053490 |
Ethyl 5-bromothieno[2,3-b]pyridine-2-carboxylate |
|
R2053491 |
4-bromo-2-(bromomethyl)thieno[2,3-c]pyridine |
|
R2053492 |
4-Chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine |
|
R2053493 |
4-Hydroxyphenylboronic acid |
|
R2053494 |
2-Hydrazinylpyrazine |
|
R2053495 |
2-Aminopyrimidine-5-boronic acid |
|
R2053496 |
2-Bromo-4-methylpyridine |
|
R2053497 |
2-(3-Chloropropoxy)-1-methoxy-4-nitrobenzene |
|
R2053498 |
trans-4-(Trifluoromethyl)cyclohexanol |
|
R2053499 |
(2,5-dioxopyrrolidin-1-yl) but-2-enoate |
|
R2053471 |
Meplazumab |
Meplazumab, also known as Mepozumab in Chinese, was developed by Chen Zhinan, an
|
R2053480 |
DBPR114;BPR1K871 |
BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM
|
R2053481 |
TBAJ-587-1 |
TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth wi
|
R2053486 |
ACT-1002-1237(S,S) |
|
R2053487 |
ACT-1002-1237(R,S) |
|
R2080711 |
BMS-1001 hydrochloride |
BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune che
|
R2053500 |
CMD178 |
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and S
|
R2053501 |
Cyclo(RGDfK) |
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an
|
R2053502 |
BK-1361(BK1361,cyclo-RLsKDK) |
Bk-1361 (BK1361, cyclo-RlSKDK) is a cyclic peptide with RLsKDK (s= D-serine), wh
|
R2053503 |
BQ-123 |
BQ-123 is a selective endothelin A receptors (ETAR) antagonist with an IC50 valu
|
R2053504 |
Ezatiostat (TER199 free base; TLK199) |
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and
|
R2053505 |
Murepavadin |
Murepavadin (POL7080) is a highly effective, specific pseudomonas macrocystis an
|
R2053506 |
Fmoc-L-Ser((Ac)3-β-D-GlcNAc)-OH |
|
R2053507 |
Fmoc-L-Thr(β-D-GlcNAc(Ac)3)-OH |
|
R2053508 |
MV1 |
MV1 is an antagonist of IAP (inhibitor of apoptosis protein), leads to protein k
|